|
Metabolomic Characterization of Fungi
|
Research Initiative
|
CDC
|
NIEHS, NIAID
|
The NIEHS and CDC''s National Institute for Occupational Safety and Health are jointly interested in examining the feasibility of using nuclear magnetic resonance to characterize air samples of fungi.
|
|
Microbiological Testing of Live Biotherapeutic Products
|
Resource Development
|
FDA
|
NIAID
|
The research and manufacturing community has a need for regulatory tools to determine the identity, potency, and purity of new probiotic products currently under development. This project will develop tools for identifying these products, therefore satisfying one of the regulatory requirements for product characterization needed by the FDA for evaluation.
|
|
Microbiome Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
OD/DPCPSI, NHGRI, OD/DPCPSI/OSC
|
The purpose of the Microbiome Interagency Working Group (MIWG) is to develop a Federal Strategic Plan for microbiome research. The Plan should use the needs, gaps, and Report’s recommendations as a foundation, taking into account how future Federal actions could benefit from an understanding of and engagement with current international activities. The Plan should provide recommendations for improving coordination of microbiome research among Federal agencies and also between Federal agencies and non-Federal domestic and international microbiome research efforts. The MIWG will also strive to enhance the Federal R&D enterprise by embracing diversity, recognizing that inclusion of a broad range of backgrounds and perspectives is critical to achieving robust intellectual dialogue.
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing
|
Research Initiative
|
FDA
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/ORWH
|
The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans.
|
|
Microsystems Team
|
Research Initiative
|
FDA
|
NIDDK, NCATS, NCI, NIBIB, NICHD, NIEHS, NINDS
|
The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund and participating NIH IC''s, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics.
|
|
Mind Your Risks
|
Public Education Campaign
|
CDC, CMS
|
NINDS
|
The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia.
|
|
Models of Infectious Disease Agent Study (MIDAS)
|
Research Initiative
|
CDC
|
NIGMS, FIC, NIAID
|
Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models will be useful to public health workers and researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid in our understanding of the disease and its spread.
|
|
Monthly NHLBI/BARDA/DoD Meeting
|
Meeting/ Workshop
|
OS
|
NHLBI
|
BARDA is funding pathogen reduction in response to the ebola epidemic and meets monthly with the DoD and NHLBI to discuss.
|
|
Mortality Disparities of American Communities
|
Health Survey
|
CDC
|
NIA, NCI, NHLBI
|
A national, longitudinal, mortality study to study the effects of differentials in demographic and socio-economic characteristics on mortality.
|
|
mPOWER mHealth Group
|
Research Initiative
|
CDC, CMS, FDA, HRSA, IHS
|
NINR, CIT, FIC, NCCIH, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR
|
Mobilizing Research supports the development, promotion, and dissemination of a wireless health research recruitment and data platform. In addition to being a primary data collection mechanism, the platform would be a data repository for both basic and applied health science, making validation and standardization of mobile health tools accessible.
|